Esperion Therape Stock Price, News & Analysis

ESPERION (NASDAQ:ESPR) reported a remarkable third quarter 2020, highlighting over 500% script growth for NEXLETOL® and NEXLIZET®. U.S. product revenue surged to $3.8 million, up from $1.0 million in Q3 2019. Despite COVID-19 challenges, the company noted significant medical community recognition, with its products included in updated lipid guidelines. Additionally, Daiichi Sankyo Europe launched NILEMDO™ and NUSTENDI™ in Germany, expanding their European reach. However, ESPERION recorded a net loss of $85.4 million for the quarter, an increase from $68.4 million year-over-year.

Esperion (NASDAQ: ESPR) announced participation in three virtual conferences in November 2020. Key events include the Credit Suisse 29th Annual Virtual Healthcare Conference on November 9 at 2:00 p.m. ET, the Stifel Virtual Healthcare Conference on November 17 at 8:40 a.m. ET, and the Jefferies Virtual London Healthcare Conference on November 18 at 9:40 a.m. ET. Each conference will feature a fireside chat and 1:1 investor meetings. Webcasts will be available on the company's investor relations site and archived for 90 days.

Esperion (NASDAQ: ESPR) is set to announce its third quarter 2020 financial results on November 2, 2020, after market close. Following the announcement, management will hold a conference call at 4:30 p.m. ET to discuss the outcomes and business developments. The call can be accessed by dialing the specified numbers, and a live audio webcast will be available on their investor website. Esperion is focused on developing oral LDL-C lowering medications to address cardiovascular disease, which affects a significant portion of the U.S. population.

Esperion (NASDAQ: ESPR) announced positive results from pooled data at the EAS 2020 Congress, showing NEXLETOL® (bempedoic acid) achieved a 22% mean reduction in LDL-C levels for patients with Heterozygous Familial Hypercholesterolemia (HeFH) after 12 weeks. The trials included over 3,000 patients and highlighted that many HeFH patients do not achieve adequate LDL-C lowering despite existing therapies. NEXLETOL, the first oral non-statin LDL-C lowering medication approved in nearly 20 years, was noted for its tolerability and lack of new safety signals.

Esperion (NASDAQ: ESPR) launched the "Break the Cycle with NEXLETOL" DTC campaign to raise awareness about its cholesterol-lowering drug, NEXLETOL (bempedoic acid), amid challenges from the COVID-19 pandemic. NEXLETOL, approved by the FDA in February 2020, is the first non-statin LDL-C lowering pill in almost 20 years, targeting adults with familial hypercholesterolemia or atherosclerotic cardiovascular disease. The campaign aims to help the 18 million U.S. patients who need further LDL-C reduction despite current treatments, showcasing NEXLETOL as a significant solution.

Esperion (NASDAQ: ESPR) has launched the "Break the Cycle with NEXLETOL" campaign to raise awareness of its LDL-C lowering medication, NEXLETOL® (bempedoic acid), which is the first oral, once-daily, non-statin treatment approved in nearly 20 years. The campaign targets the approximately 18 million U.S. patients struggling to achieve cholesterol goals despite statin therapy. It uses a multichannel approach, starting with a full-page advertisement in the Wall Street Journal, to reach patients and healthcare professionals effectively.

Esperion (NASDAQ: ESPR) will participate in two virtual conferences this September. The first is the Citi 15th Annual Biopharma Conference on September 9, 2020, featuring 1:1 investor meetings. The second is the Morgan Stanley 18th Annual Global Healthcare Conference on September 14, 2020, which includes a fireside chat at 3:45 p.m. ET and additional investor meetings. A live audio webcast for the Morgan Stanley event will be available on the company's website for 90 days post-event. Esperion focuses on developing new LDL-C lowering medicines to combat cardiovascular diseases.

Esperion (NASDAQ: ESPR) announced its participation in the ESC Congress 2020, presenting pooled analyses from four Phase 3 trials and long-term data on NEXLETOL (bempedoic acid). The presentations will cover its effects on uric acid in patients and the drug's long-term safety and efficacy. NEXLETOL was recently approved by the FDA and European Commission, with European availability expected by Q4 2020. This medicine represents a significant advancement as a non-statin LDL-C lowering option for patients at high risk of cardiovascular events.

On August 19, 2020, Esperion (NASDAQ: ESPR) granted 25,566 restricted stock units (RSUs) to 28 new employees under its 2017 Inducement Equity Incentive Plan. This plan is designed to attract new talent by granting equity awards to individuals not previously associated with the company. The RSUs vest over a four-year period, with 25% vesting on the one-year anniversary and the remaining 75% vesting quarterly. Esperion focuses on developing oral medications to lower LDL-C levels to combat cardiovascular disease, which affects over 96 million adults in the U.S.